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Identity 
Other names: TAOS1 




The ORAOV1 gene spans 9.75 Kb genomic DNA and 
consists of 5 known exons. The coding sequence of 
ORAOV1 is 414 nucleotides long. 
Transcription 
So far, there is one reported transcript variant of 
ORAOV1 caused by alternative exon utilization. The 
production of transcript variant 1, which is  
named as ORAOV1-A, is produced by alternative 
splicing of exon 3. An in-frame stop codon in exon 4 
indicates that the ORAOV1 protein isoform 1 may be 
interrupted at this position. Interestingly, an association 
between the expression level of this ORAOV1 gene 
ORAOV1-A and the differentiation  
degree of oral squamous cell carcinoma has been 
observed in a Chinese patient cohort. 
Protein 
Note 
So far, no study describes the location of ORAOV1 
protein in cells or tissues. 
Function 
Apoptosis, but whether it belongs to extrinsic or intrisic 
pathway is yet unknown. 
Implicated in 
Oral squamous cell carcinoma 
Note 
ORAOV1 gene may be a candidate biomarker for 
diagnosis and prognosis in oral squamous cell 
carcinoma (OSCC). This finding was made based on a 
study using PCR to measure ORAOV1 in 15 healthy 
oral mucosa tissue samples, 30 OLK tissues samples, 
and 33 OSCC tissue samples.  
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Figure 1 : ORAOV1 gene consists of five exons and spans 9.75 kb of genomic DNA. 
Figure 2 : (A) The schematic structures of the ORAOV1 gene and its two transcript variants. ORAOV1 has five exons. The two ORAOV1 
splice variants consist of different exon combinations that produce different protein-coding regions. (B) Comparison of ORAOV1 with 
ORAOV1-A nucleotide sequence. White boxes show amino acid differences. 
 
The authors found that ORAOV1 amplification was 
significant-ly associated with larger tumor size, 
presence of lymph node metastasis, poor histological 
differen-tiation and advanced clinical stage. Therefore, 
they suggested the potential roles of ORAOV1 in oral 
carcinogenesis. Further studies about the biological 
functional role of ORAOV1 in OSCC tumori-genesis 
showed that ORAOV1 plays pivotal roles in the growth 
and angiogenesis of OSCC. The authors performed a 
loss-of-function study by using small interfering RNA 
(siRNA) against ORAOV1 in two OSCC cell lines. 
They found that the OSCC cells with reduced 
ORAOV1 showed retarded cell growth in vitro and 
displayed inhibition in both tumor growth and tumor 
angiogenesis in vivo. Further analyses reveal that the 
retarded cell growth is associated with an increase in 
apoptosis involving the activation of caspase 3-
dependent pathway, and a cell cycle arrest at the S-
phase with a downregulation of cyclin A, cyclin B1, 
and CDC2. The suppressed tumor growth in vivo may 
be attributed to synergistic effect between inhibition in 
cell growth and suppression of tumor angio-genesis.  
The latter is most likely due to a suppression of VEGF. 
The study of the novel splice variant of ORAOV1, 
ORAOV1-A, showed that there was an inverse 
correlation between the expression frequency of 
ORAOV1-A and the degree of differentiation in OSCC. 
This result suggested that ORAOV1-A may play a 
functional role in the tumorigenesis of OSCC, and the 
ORAOV1-A expression may serve as an adjunctive 
prognostic indicator for patients with OSCC. 
Esophageal squamous cell carcinoma 
Note 
ORAOV1 is supposed to serve as a new marker for 
predicting the malignancy of esophageal SCC. This 
finding was made based on a study using quantitative 
RT-PCR to examine the ORAOV1 gene expression 
level in 38 esophageal SCCs. The authors found that 
the ORAOV1 overexpression correlated with the 
clinicopathological features of esophageal SCCs, which 
revealed a significant difference in lymph node 
metastasis and a trend towards advanced TNM stages. 
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